Long-Term Response to a Bioactive Biphasic Biomaterial in the Femoral Neck of Osteoporotic Rats
Authors:
- Deepak Bushan RainaDeepak Bushan Raina
- Aurimas ŠirkaAŠAurimas Širka
- Irfan QayoomIQIrfan Qayoom
- Arun Kumar TeotiaATArun Kumar Teotia
- Yang LiuYLYang Liu
- Sarunas TaraseviciusSTSarunas Tarasevicius
- Kathleen Elizabeth TannerKTKathleen Elizabeth Tanner
- Hanna IsakssonHIHanna Isaksson
- Ashok KumarAKAshok Kumar
- Magnus TägilMTMagnus Tägil
- Lars LidgrenLLLars Lidgren
Open Access
- 19 October 2020
- journal article
- research article
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 26 (19-20) , 1042-1051
Abstract
Osteoporosis often leads to fragility fractures of the hip, resulting in impaired quality of life and increased mortality. Augmenting the proximal femur could be an attractive option for prevention of fracture or fixation device failure. We describe a tissue engineering based strategy to enhance long-term bone formation in the femoral neck of osteoporotic rats by locally delivering bioactive molecules; recombinant human bone morphogenic protein-2 (rhBMP-2), and zoledronic acid (ZA) by using a calcium sulfate/hydroxyapatite (CaS/HA) biomaterial. A defect was created by reaming the femoral neck canal of osteoporotic (OVX) rats and they were treated as follows: G1. Empty, G2. CaS/HA, G3. CaS/HA+Systemic ZA, G4. CaS/HA+Local ZA, and G5. CaS/HA+Local ZA+rhBMP-2. Bone formation was evaluated 6 months after treatment. Further, radioactively labeled 14 C-ZA was used to study the bioavailability of ZA at the defect location, which was determined by using scintillation counting. Micro-CT indicated significantly higher bone volume in groups G4 and G5 compared with the other treatment groups. This was confirmed qualitatively by histological assessment. Addition of rhBMP-2 gave no additional benefit in this model. Local delivery of ZA performed better than systemic administration of ZA. Mechanical testing showed no differences between the groups, likely reflecting that the addition of bioactive molecules had limited effect on cortical bone or the choice of mechanical testing setup was not optimal. Scintillation counting revealed higher amounts of 14 C-ZA present in the treated leg of G4 compared with its contralateral control and compared with G3, indicating that local ZA delivery can be used to achieve high local concentrations without causing a systemic effect. This long-term study shows that local delivery of ZA using a CaS/HA carrier can regenerate cancellous bone in the femoral neck canal and has clear implications for enhancing implant integration and fixation in fragile bone.Keywords
This publication has 29 references indexed in Scilit:
- Calcium Sulphate/Hydroxyapatite Carrier for Bone Formation in the Femoral Neck of Osteoporotic RatsTissue Engineering Part A, 2018
- Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistanceProceedings of the National Academy of Sciences, 2017
- Bisphosphonates adherence for treatment of osteoporosisInternational Archives of Medicine, 2013
- Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA)Osteoporosis International, 2011
- The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized ratsBiomaterials, 2009
- Mortality following hip fracture: Trends and geographical variations over the last 40 yearsInjury, 2008
- Osteoporosis epidemiology updateCurrent Rheumatology Reports, 2008
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Estimating Hip Fracture Morbidity, Mortality and CostsJournal of the American Geriatrics Society, 2003
- Hip fractures in the elderly: A world-wide projectionOsteoporosis International, 1992